Acknowledgment of Support
This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Live Medical Crossfire®: Improving Prognosis in SSc-ILD: Best Practices in Diagnosis, Optimizing Clinical Management, and Efficient Patient Communication
Release Date: June 15, 2021
Expiration Date: June 15, 2022
Activity Overview
This online, on-demand virtual symposium brings together renowned experts in systemic sclerosis–associated interstitial lung disease (SSc-ILD). In this educational program, these experts use a case-based format to discuss characteristic findings of SSc-ILD, monitoring for disease progression, and best treatment approaches, including recently approved agents for SSc-ILD. As these therapies may only slow disease progression, insights on communication strategies for setting treatment expectations will be shared.
This educational activity is an archive of the live virtual symposium held on May 19, 2021.
Acknowledgement of Commercial Support
This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate. |
Target Audience
Learning Objectives
- Review the pathophysiology of SSc-ILD and the implications that new insights have for diagnosing and treating the disease.
- Recognize key risk factors and diagnostic tests that could improve early symptom recognition and prognosis of the disease.
- Evaluate key data on new and emerging treatment options for SSc-ILD to properly educate patients.
- Implement team-based strategies to improve individualization of treatment plans for patients with SSc-ILD.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.
Faculty
Medical Director, Advanced Lung
Disease and Transplant Program
Inova Fairfax Hospital
Falls Church, VA
Disclosures: Consultant: Bellerophon, Boehringer Ingelheim, Galapagos, Roche Genentech, United Therapeutics; Speakers’ Bureau: Boehringer Ingelheim, Roche Genentech.
Director, Rheumatic Lung Disease Program
Cleveland Clinic
Cleveland, OH
Disclosures: Grant/Research Support: Acceleron, Boehringer Ingelheim, Gossamer Bio, Reata, United Therapeutics, Viela Bio; Consultant: Actelion, Boehringer Ingelheim, United Therapeutics; Speakers’ Bureau: Actelion, Bayer, United Therapeutics.
Assistant Professor of Medicine
Director, Interstitial Lung Disease Program
University of California, Davis
Davis, CA
Disclosures: Grant/Research Support: NHLBI K23; Consultant: AmMax Bio, Boehringer Ingelheim, Lupin Research.
Associate Professor of Medicine
Autoimmune Lung Center and Interstitial Lung Disease Program
National Jewish Health
Denver, CO
Disclosures: Joshua Solomon, MD, has no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.
